5.87 0.06 (1.03%) | 11-09 00:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 7.58 | 1-year : | 8.85 |
Resists | First : | 6.48 | Second : | 7.58 |
Pivot price | 5.97 | |||
Supports | First : | 5.59 | Second : | 5.03 |
MAs | MA(5) : | 5.86 | MA(20) : | 5.95 |
MA(100) : | 5.17 | MA(250) : | 4.7 | |
MACD | MACD : | 0 | Signal : | 0.1 |
%K %D | K(14,3) : | 32.2 | D(3) : | 33.9 |
RSI | RSI(14): 53.5 | |||
52-week | High : | 7.54 | Low : | 2.79 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SBTX ] has closed above bottom band by 32.2%. Bollinger Bands are 37.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 6.16 - 6.19 | 6.19 - 6.22 |
Low: | 5.74 - 5.78 | 5.78 - 5.81 |
Close: | 5.81 - 5.87 | 5.87 - 5.92 |
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Thu, 25 Apr 2024
Silverback Therapeutics (NASDAQ:SBTX) Trading Down 2.8% - Defense World
Sun, 23 Oct 2022
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERI - EIN News
Thu, 11 Aug 2022
Do Analysts Agree Thursday on Silverback Therapeutics Inc (SBTX) Stock's Target Price? - InvestorsObserver
Thu, 21 Jul 2022
Silverback Therapeutics Inc (SBTX) Down 1.80% in Premarket Trading - InvestorsObserver
Thu, 21 Jul 2022
Silverback Therapeutics and ARS Pharmaceuticals Announce Merger - Business Wire
Thu, 31 Mar 2022
Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results - Business Wire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 35 (M) |
Shares Float | 22 (M) |
Held by Insiders | 1.6 (%) |
Held by Institutions | 80.1 (%) |
Shares Short | 898 (K) |
Shares Short P.Month | 543 (K) |
EPS | -2.74 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 7.92 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -17.2 % |
Return on Equity (ttm) | -28.8 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -2.54 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -75 (M) |
Levered Free Cash Flow | -43 (M) |
PE Ratio | -2.16 |
PEG Ratio | 0 |
Price to Book value | 0.74 |
Price to Sales | 0 |
Price to Cash Flow | -2.77 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |